91 related articles for article (PubMed ID: 22888961)
41. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited.
Kebebew E; Treseler PA; Ituarte PH; Clark OH
World J Surg; 2001 May; 25(5):632-7. PubMed ID: 11369991
[TBL] [Abstract][Full Text] [Related]
42. [Therapy concept in differentiated thyroid gland carcinoma--results of 25 years with 257 patients].
Gemsenjäger E; Heitz PU; Martina B; Schweizer I
Praxis (Bern 1994); 2000 Nov; 89(44):1779-97. PubMed ID: 11109916
[TBL] [Abstract][Full Text] [Related]
43. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.
Cappelli C; Pirola I; Braga M; De Martino E; Morassi ML; Gandossi E; Mattanza C; Balzano R; Castellano M; Rosei EA
Ann Ital Chir; 2006; 77(2):107-13. PubMed ID: 17147082
[TBL] [Abstract][Full Text] [Related]
44. [Expression of mucin-l and beta-catenin in papillary thyroid carcinoma and the clinical significance thereof].
He F; Li H; Li WS; Dong XH
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(6):393-6. PubMed ID: 19567117
[TBL] [Abstract][Full Text] [Related]
45. Clinical characteristics of poorly differentiated thyroid carcinomas compared with those of classical papillary thyroid carcinomas.
Lin JD; Chao TC; Hsueh C
Clin Endocrinol (Oxf); 2007 Feb; 66(2):224-8. PubMed ID: 17223992
[TBL] [Abstract][Full Text] [Related]
46. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
[TBL] [Abstract][Full Text] [Related]
47. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
48. Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer.
Sáez C; Martínez-Brocca MA; Castilla C; Soto A; Navarro E; Tortolero M; Pintor-Toro JA; Japón MA
J Clin Endocrinol Metab; 2006 Apr; 91(4):1404-9. PubMed ID: 16418208
[TBL] [Abstract][Full Text] [Related]
49. Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer.
Basolo F; Pinchera A; Fugazzola L; Fontanini G; Elisei R; Romei C; Pacini F
Eur J Cancer; 1994; 30A(2):171-4. PubMed ID: 7908818
[TBL] [Abstract][Full Text] [Related]
50. The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells.
Read ML; Seed RI; Fong JC; Modasia B; Ryan GA; Watkins RJ; Gagliano T; Smith VE; Stratford AL; Kwan PK; Sharma N; Dixon OM; Watkinson JC; Boelaert K; Franklyn JA; Turnell AS; McCabe CJ
Endocrinology; 2014 Apr; 155(4):1222-34. PubMed ID: 24506068
[TBL] [Abstract][Full Text] [Related]
51. Retinoblastoma protein and proliferating-cell nuclear antigen expression as predictors of recurrence in well-differentiated papillary thyroid carcinoma.
Omura K; Nagasato A; Kanehira E; Kinsen H; Amaya S; Kimura K; Kajita T; Nozaki Y; Mizukami Y; Nonomura A; Watanabe Y
J Clin Oncol; 1997 Dec; 15(12):3458-63. PubMed ID: 9396398
[TBL] [Abstract][Full Text] [Related]
52. Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer.
Read ML; Fong JC; Modasia B; Fletcher A; Imruetaicharoenchoke W; Thompson RJ; Nieto H; Reynolds JJ; Bacon A; Mallick U; Hackshaw A; Watkinson JC; Boelaert K; Turnell AS; Smith VE; McCabe CJ
Oncogene; 2017 Sep; 36(37):5296-5308. PubMed ID: 28504713
[TBL] [Abstract][Full Text] [Related]
53. The proto-oncogene PBF binds p53 and is associated with prognostic features in colorectal cancer.
Read ML; Seed RI; Modasia B; Kwan PP; Sharma N; Smith VE; Watkins RJ; Bansal S; Gagliano T; Stratford AL; Ismail T; Wakelam MJ; Kim DS; Ward ST; Boelaert K; Franklyn JA; Turnell AS; McCabe CJ
Mol Carcinog; 2016 Jan; 55(1):15-26. PubMed ID: 25408419
[TBL] [Abstract][Full Text] [Related]
54. Pro-invasive Effect of Proto-oncogene PBF Is Modulated by an Interaction with Cortactin.
Watkins RJ; Imruetaicharoenchoke W; Read ML; Sharma N; Poole VL; Gentilin E; Bansal S; Bosseboeuf E; Fletcher R; Nieto HR; Mallick U; Hackshaw A; Mehanna H; Boelaert K; Smith VE; McCabe CJ
J Clin Endocrinol Metab; 2016 Dec; 101(12):4551-4563. PubMed ID: 27603901
[TBL] [Abstract][Full Text] [Related]
55. PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival.
Repo H; Gurvits N; Löyttyniemi E; Nykänen M; Lintunen M; Karra H; Kurki S; Kuopio T; Talvinen K; Söderström M; Kronqvist P
BMC Cancer; 2017 Oct; 17(1):705. PubMed ID: 29078751
[TBL] [Abstract][Full Text] [Related]
56. PTTG1IP (PBF) is a prognostic marker and correlates with immune infiltrate in ovarian cancer.
Ma R; Tang Z; Wang J
Am J Transl Res; 2023; 15(1):27-46. PubMed ID: 36777854
[TBL] [Abstract][Full Text] [Related]
57. Sp4 Regulates
Dai X; Luo S; Guo S; Zhou W; Song W
DNA Cell Biol; 2022 Dec; 41(12):1053-1062. PubMed ID: 36383136
[TBL] [Abstract][Full Text] [Related]
58. Functional consequences of the first reported mutations of the proto-oncogene PTTG1IP/PBF.
Imruetaicharoenchoke W; Fletcher A; Lu W; Watkins RJ; Modasia B; Poole VL; Nieto HR; Thompson RJ; Boelaert K; Read ML; Smith VE; McCabe CJ
Endocr Relat Cancer; 2017 Sep; 24(9):459-474. PubMed ID: 28676500
[TBL] [Abstract][Full Text] [Related]
59. SURVIVIN POSITIVITY AND PROGNOSTIC FACTORS IN PAPILLARY THYROID CARCINOMAS.
Keskin EU; Taştekin E; Can N; Mut AN; Celik M; Bulbul BY; Puyan FO; Ozyilmaz F; Guldiken S; Ayturk S; Sezer A; Üstün F
Acta Endocrinol (Buchar); 2021; 17(4):455-461. PubMed ID: 35747869
[TBL] [Abstract][Full Text] [Related]
60. PBF, a Proto-oncogene in Esophageal Carcinoma.
Lian SH; Song JD; Huang Y
Open Med (Wars); 2019; 14():748-756. PubMed ID: 31637306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
